{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:16:09Z","timestamp":1787026569557,"version":"build-2736575974"},"reference-count":161,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82460324, 82101877"],"award-info":[{"award-number":["82460324, 82101877"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004607","name":"Natural Science Foundation of Guangxi Province","doi-asserted-by":"publisher","award":["2024GXNSFAA010096"],"award-info":[{"award-number":["2024GXNSFAA010096"]}],"id":[{"id":"10.13039\/501100004607","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2025A1515012661"],"award-info":[{"award-number":["2025A1515012661"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017610","name":"Shenzhen Science and Technology Innovation Program","doi-asserted-by":"publisher","award":["JCYJ20230807150913027, JCYJ20240813165111016"],"award-info":[{"award-number":["JCYJ20230807150913027, JCYJ20240813165111016"]}],"id":[{"id":"10.13039\/501100017610","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005145","name":"Basic Research Program of Jiangsu Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005145","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Autoimmune diseases are complex disorders caused by the interaction between the immune system and self-antigens, involving genetic, environmental triggers, and other cellular factors. The programmed cell death receptor-1 (PD-1) gene, as a critical factor in immune regulation, has garnered significant attention in the study of autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and ankylosing spondylitis. Although the pathogenesis of these diseases varies, they all manifest as a breakdown in immune tolerance and an imbalance in immune homeostasis. Research has shown that in the development of autoimmune diseases, changes in PD-1 gene expression, its binding with PD-L1 and PD-L2, and signal transduction pathways are often abnormal. These abnormalities may lead to the overactivation of T cells and B cells, resulting in the attack on self-tissues. Consequently, therapeutic strategies targeting the PD-1\/PD-L1 signaling pathway hold promising potential. Gene therapy approaches or small-molecule drugs that enhance PD-L1 transcription could strengthen PD-1\/PD-L1 binding and restore inhibitory signaling, thereby rebalancing immune responses and improving patients\u2019 quality of life. Additionally, recent studies suggest that targeting V\u03b34\u03b3\u03b4T cells to monitor disease progression and prognosis represents another potential PD-1-based therapeutic strategy. This review focuses on the role of the PD-1 gene in autoimmune diseases, systematically elaborating on the structure, molecular functions, and regulatory mechanisms of PD-1 and its ligands, while providing an in-depth analysis of PD-1\u2019s mechanistic involvement in autoimmune diseases and its therapeutic prospects.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1707084","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T06:47:02Z","timestamp":1771915622000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["The role of programmed cell death 1 in autoimmune diseases: mechanisms and therapeutic implications"],"prefix":"10.3389","volume":"17","author":[{"given":"Zhenyu","family":"Liu","sequence":"first","affiliation":[{"name":"Laboratory Center, Guangxi Key Laboratory of Metabolic Reprogramming and Intelligent Medical Engineering for Chronic Diseases, the Second Affiliated Hospital of Guilin Medical University","place":["Guilin, China"]},{"name":"Department of Nuclear Medicine, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zipeng","family":"Hu","sequence":"additional","affiliation":[{"name":"Laboratory Center, Guangxi Key Laboratory of Metabolic Reprogramming and Intelligent Medical Engineering for Chronic Diseases, the Second Affiliated Hospital of Guilin Medical University","place":["Guilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilin","family":"Lao","sequence":"additional","affiliation":[{"name":"Laboratory Center, Guangxi Key Laboratory of Metabolic Reprogramming and Intelligent Medical Engineering for Chronic Diseases, the Second Affiliated Hospital of Guilin Medical University","place":["Guilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lemin","family":"Chen","sequence":"additional","affiliation":[{"name":"Laboratory Center, Guangxi Key Laboratory of Metabolic Reprogramming and Intelligent Medical Engineering for Chronic Diseases, the Second Affiliated Hospital of Guilin Medical University","place":["Guilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wen","sequence":"additional","affiliation":[{"name":"Laboratory Center, Guangxi Key Laboratory of Metabolic Reprogramming and Intelligent Medical Engineering for Chronic Diseases, the Second Affiliated Hospital of Guilin Medical University","place":["Guilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqiang","family":"Liang","sequence":"additional","affiliation":[{"name":"Laboratory Center, Guangxi Key Laboratory of Metabolic Reprogramming and Intelligent Medical Engineering for Chronic Diseases, the Second Affiliated Hospital of Guilin Medical University","place":["Guilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Laboratory Center, Guangxi Key Laboratory of Metabolic Reprogramming and Intelligent Medical Engineering for Chronic Diseases, the Second Affiliated Hospital of Guilin Medical University","place":["Guilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianliang","family":"Hou","sequence":"additional","affiliation":[{"name":"Laboratory Center, Guangxi Key Laboratory of Metabolic Reprogramming and Intelligent Medical Engineering for Chronic Diseases, the Second Affiliated Hospital of Guilin Medical University","place":["Guilin, China"]},{"name":"Department of Central Laboratory, Shenzhen Hospital, Beijing University of Chinese Medicine","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1100359","article-title":"Systemic lupus erythematosus","volume":"365","author":"Tsokos","year":"2011","journal-title":"New Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/35079107","article-title":"Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn\u2019s disease","volume":"411","author":"Hugot","year":"2001","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1006\/clin.1997.4412","article-title":"Epidemiology and estimated population burden of selected autoimmune diseases in the United States","volume":"84","author":"Jacobson","year":"1997","journal-title":"Clin Immunol Immunopathol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.molimm.2023.12.010","article-title":"Single-cell transcriptional profiling reveals aberrant gene expression patterns and cell states in autoimmune diseases","volume":"165","author":"Liu","year":"2024","journal-title":"Mol Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B6","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/ni1443","article-title":"The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection","volume":"8","author":"Sharpe","year":"2007","journal-title":"Nat Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/j.1600-065X.2009.00769.x","article-title":"Yin-Yang of costimulation: crucial controls of immune tolerance and function","volume":"229","author":"Nurieva","year":"2009","journal-title":"Immunol Rev"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxm057","article-title":"PD-1 and PD-1 ligands: from discovery to clinical application","volume":"19","author":"Okazaki","year":"2007","journal-title":"Int Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/70932","article-title":"B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion","volume":"5","author":"Dong","year":"1999","journal-title":"Nat Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0712278105","article-title":"The PD-1\/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors","volume":"105","author":"Lin","year":"2008","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.10.5538","article-title":"Expression of programmed death 1 ligands by murine T cells and APC","volume":"169","author":"Yamazaki","year":"2002","journal-title":"J Immunol (Baltimore Md.: 1950)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-02084-y","article-title":"Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy","volume":"128","author":"Wang","year":"2023","journal-title":"Br J Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-16-1761","article-title":"PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer","volume":"23","author":"Yearley","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1245\/s10434-015-4903-7","article-title":"Clinicopathologic analysis of PD-L1 and PD-L2 expression in renal cell carcinoma: association with oncogenic proteins status","volume":"23","author":"Shin","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/s40425-019-0703-0","article-title":"A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma","volume":"7","author":"Zhang","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-16-0031","article-title":"Immune profiling of adenoid cystic carcinoma: PD-L2 expression and associations with tumor-infiltrating lymphocytes","volume":"4","author":"Sridharan","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-024-01317-2","article-title":"PD-L2 drives resistance to EGFR-TKIs: dynamic changes of the tumor immune environment and targeted therapy","volume":"31","author":"Wang","year":"2024","journal-title":"Cell Death Differ"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2015.09.010","article-title":"Structure of the complex of human programmed death 1, PD-1, and its ligand PD-L1","volume":"23","author":"Zak","year":"2015","journal-title":"Struct (London England: 1993)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/gene.2008.19","article-title":"Analysis of the functional relevance of a putative regulatory SNP of PDCD1, PD1.3, associated with systemic lupus erythematosus","volume":"9","author":"Suarez-Gestal","year":"2008","journal-title":"Genes Immun"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2022.100907","article-title":"Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1\/PD-L1 blockade","volume":"66","author":"Pang","year":"2023","journal-title":"Drug Resist Updates"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.683249","article-title":"Total Glucosides of Paeony Ameliorate Pristane-Induced Lupus Nephritis by Inducing PD-1 ligands(+) Macrophages via Activating IL-4\/STAT6\/PD-L2 Signaling","volume":"12","author":"Liang","year":"2021","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-024-02182-1","article-title":"The miRNA and PD-1\/PD-L1 signaling axis: an arsenal of immunotherapeutic targets against lung cancer","volume":"10","author":"Yadav","year":"2024","journal-title":"Cell Death Discov"},{"key":"B24","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.25.21.9543-9553.2005","article-title":"CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms","volume":"25","author":"Parry","year":"2005","journal-title":"Mol Cell Biol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.731175","article-title":"Targeting tim-3 in cancer with resistance to PD-1\/PD-L1 blockade","volume":"11","author":"Tian","year":"2021","journal-title":"Front Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.7150\/jca.77619","article-title":"Clinical implications of the interaction between PD-1\/PD-L1 and PI3K\/AKT\/mTOR pathway in progression and treatment of non-small cell lung cancer","volume":"13","author":"Quan","year":"2022","journal-title":"J Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1296341","article-title":"PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment","volume":"14","author":"Parvez","year":"2023","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01088","article-title":"Looking for the optimal PD-1\/PD-L1 inhibitor in cancer treatment: A comparison in basic structure, function, and clinical practice","volume":"11","author":"Chen","year":"2020","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00011-010-0233-1","article-title":"Intrahepatic levels of PD-1\/PD-L correlate with liver inflammation in chronic hepatitis B","volume":"60","author":"Chen","year":"2011","journal-title":"Inflammation Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.01.001","article-title":"Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments","volume":"40","author":"Kumagai","year":"2022","journal-title":"Cancer Cell"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1323797","article-title":"The implication of targeting PD-1:PD-L1 pathway in treating sepsis through immunostimulatory and anti-inflammatory pathways","volume":"14","author":"Chen","year":"2023","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"5383","DOI":"10.3390\/cancers15225384","article-title":"Overcoming immune checkpoint therapy resistance with SHP2 inhibition in cancer and immune cells: A review of the literature and novel combinatorial approaches","volume":"15","author":"Tojjari","year":"2023","journal-title":"Cancers"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-023-00867-9","article-title":"Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1","volume":"23","author":"Chamoto","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/s41551-019-0360-0","article-title":"Depletion of PD-1-positive cells ameliorates autoimmune disease","volume":"3","author":"Zhao","year":"2019","journal-title":"Nat Biomed Eng"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.797172","article-title":"Intralymphatic GAD-alum injection modulates B cell response and induces follicular helper T cells and PD-1+ CD8+ T cells in patients with recent-onset type 1 diabetes","volume":"12","author":"Barcenilla","year":"2021","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.05.042","article-title":"FOXP3 controls regulatory T cell function through cooperation with NFAT","volume":"126","author":"Wu","year":"2006","journal-title":"Cell"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e3001272","DOI":"10.1371\/journal.pbio.3001272","article-title":"Programmed cell death 1 ligand (PD-L1) on T cells generates Treg suppression from memory","volume":"19","author":"Kazanova","year":"2021","journal-title":"PloS Biol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-12-889725","article-title":"NCAM1 (CD56) promotes leukemogenesis and confers drug resistance in AML","volume":"133","author":"Sasca","year":"2019","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1402550","article-title":"NF-\u03baB regulates PD-1 expression in macrophages","volume":"194","author":"Bally","year":"2015","journal-title":"J Immunol (Baltimore Md.: 1950)"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114401","article-title":"IRF4 impedes human CD8 T cell function and promotes cell proliferation and PD-1 expression","volume":"43","author":"Hirsch","year":"2024","journal-title":"Cell Rep"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.76183","article-title":"FER-mediated phosphorylation and PIK3R2 recruitment on IRS4 promotes AKT activation and tumorigenesis in ovarian cancer cells","volume":"11","author":"Zhang","year":"2022","journal-title":"eLife"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2020071010","article-title":"Deletion of Myeloid Interferon Regulatory Factor 4 (Irf4) in Mouse Model Protects against Kidney Fibrosis after Ischemic Injury by Decreased Macrophage Recruitment and Activation","volume":"32","author":"Sasaki","year":"2021","journal-title":"J Am Soc Nephrol: JASN"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2011.01.010","article-title":"MicroRNA-146a regulates the maturation process and pro-inflammatory cytokine secretion by targeting CD40L in oxLDL-stimulated dendritic cells","volume":"585","author":"Chen","year":"2011","journal-title":"FEBS Lett"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2010.09.009","article-title":"MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development","volume":"33","author":"O\u2019Connell","year":"2010","journal-title":"Immunity"},{"key":"B46","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/bs9.0000000000000149","article-title":"PD-L1: expression regulation","volume":"5","author":"Zhou","year":"2023","journal-title":"Blood Sci (Baltimore Md.)"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/mc.23587","article-title":"IL-8 correlates with nonresponse to neoadjuvant nivolumab in HPV positive HNSCC via a potential extracellular vesicle miR-146a mediated mechanism","volume":"62","author":"Hill","year":"2023","journal-title":"Mol Carcinogene"},{"key":"B48","doi-asserted-by":"publisher","first-page":"18829","DOI":"10.1038\/s41598-019-55100-2","article-title":"Elevated expression of miR-146a correlates with high levels of immune cell exhaustion markers and suppresses cellular immune function in chronic HIV-1-infected patients","volume":"9","author":"Yu","year":"2019","journal-title":"Sci Rep"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1159\/000527575","article-title":"Association between Susceptibility to Systemic Lupus Erythematous and Polymorphisms in miR-146a and miR-499: A Meta-Analysis","volume":"184","author":"Lee","year":"2023","journal-title":"Int Arch Allergy Immunol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"12767","DOI":"10.3390\/ijms241612767","article-title":"MiRNA-146a-A key player in immunity and diseases","volume":"24","author":"Gilyazova","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B51","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1038\/s41467-021-22641-y","article-title":"MicroRNA-146a limits tumorigenic inflammation in colorectal cancer","volume":"12","author":"Garo","year":"2021","journal-title":"Nat Commun"},{"key":"B52","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s12943-025-02397-5","article-title":"Post-translational modifications of cancer immune checkpoints: mechanisms and therapeutic strategies","volume":"24","author":"Jia","year":"2025","journal-title":"Mol Cancer"},{"key":"B53","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s12935-025-03809-8","article-title":"Emerging roles of non-coding RNA derived from extracellular vesicles in regulating PD-1\/PD-L1 pathway: insights into cancer immunotherapy and clinical applications","volume":"25","author":"Zhang","year":"2025","journal-title":"Cancer Cell Int"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2019.02.004","article-title":"Targeting DNA methylation and EZH2 activity to overcome melanoma resistance to immunotherapy","volume":"40","author":"Emran","year":"2019","journal-title":"Trends Immunol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13148-020-00883-9","article-title":"Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma","volume":"12","author":"Hoffmann","year":"2020","journal-title":"Clin Epigenet"},{"key":"B56","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41435-023-00196-w","article-title":"DNA methylation and transcriptome signatures of the PDCD1 gene in ankylosing spondylitis","volume":"24","author":"Wu","year":"2023","journal-title":"Genes Immun"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2019.10903","article-title":"PD-L1 expression levels on tumor cells affect their immunosuppressive activity","volume":"18","author":"Zheng","year":"2019","journal-title":"Oncol Lett"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.75.3384","article-title":"Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing","volume":"36","author":"Rizvi","year":"2018","journal-title":"J Clin Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01323-8","article-title":"A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer","volume":"27","author":"Bassez","year":"2021","journal-title":"Nat Med"},{"key":"B60","doi-asserted-by":"publisher","first-page":"7250","DOI":"10.1038\/s41467-022-34877-3","article-title":"A single-cell analysis reveals tumor heterogeneity and immune environment of acral melanoma","volume":"13","author":"Zhang","year":"2022","journal-title":"Nat Commun"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1383456","article-title":"Targeting PD-1\/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challenges","volume":"15","author":"Javed","year":"2024","journal-title":"Front Immunol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"7726","DOI":"10.3390\/ijms25147726","article-title":"Exploring the role of PD-1 in the autoimmune response: insights into its implication in systemic lupus erythematosus","volume":"25","author":"Sagrero-Fabela","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01731-z","article-title":"Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1\/PD-L1 immunotherapy for solid cancers","volume":"22","author":"Pei","year":"2023","journal-title":"Mol Cancer"},{"key":"B64","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12943-023-01845-4","article-title":"Beyond the anti-PD-1\/PD-L1 era: promising role of the BTLA\/HVEM axis as a future target for cancer immunotherapy","volume":"22","author":"Sordo-Bahamonde","year":"2023","journal-title":"Mol Cancer"},{"key":"B65","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12951-023-01966-4","article-title":"Advances in PD-1 signaling inhibition-based nano-delivery systems for tumor therapy","volume":"21","author":"Liu","year":"2023","journal-title":"J Nanobiotechnol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1111\/prd.12548","article-title":"The role of programmed death receptor (PD-)1\/PD-ligand (L)1 in periodontitis and cancer","volume":"96","author":"Groeger","year":"2024","journal-title":"Periodontol 2000"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.108","article-title":"The diverse functions of the PD1 inhibitory pathway","volume":"18","author":"Sharpe","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf1292","article-title":"T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition","volume":"355","author":"Hui","year":"2017","journal-title":"Sci (New York N.Y.)"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxs098","article-title":"PD-1 is a novel regulator of human B-cell activation","volume":"25","author":"Thibult","year":"2013","journal-title":"Int Immunol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/s1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2020.0010","article-title":"Immune function and mechanism of costimulating molecules PD-1 and OX40 in rheumatoid arthritis","volume":"40","author":"Huang","year":"2020","journal-title":"J Interferon Cytokine Res"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000000320","article-title":"Targeting neuropilin-1 abolishes anti-PD-1-upregulated regulatory T cells and synergizes with 4-1BB agonist for liver cancer treatment","volume":"78","author":"Wu","year":"2023","journal-title":"Hepatol (Baltimore Md.)"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.04.011","article-title":"Remodeling of the immune and stromal cell compartment by PD-1 blockade in mismatch repair-deficient colorectal cancer","volume":"41","author":"Li","year":"2023","journal-title":"Cancer Cell"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2010.00923.x","article-title":"The PD-1 pathway in tolerance and autoimmunity","volume":"236","author":"Francisco","year":"2010","journal-title":"Immunol Rev"},{"key":"B76","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s42358-023-00333-z","article-title":"The effect of PD-1\/PD-L1 signaling axis on the interaction between CD19(+)B cells and CD4(+)T cells in peripheral blood of patients with systemic lupus erythematosus","volume":"63","author":"Xie","year":"2023","journal-title":"Adv Rheumatol (London England)"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05220-2","article-title":"Patients with systemic lupus erythematosus show increased proportions of CD19(+)CD20(-) B cells and secretion of related autoantibodies","volume":"40","author":"Zhu","year":"2021","journal-title":"Clin Rheumatol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2020.155119","article-title":"Low expressions of PD-L1 and CTLA-4 by induced CD4(+)CD25(+) Foxp3(+) Tregs in patients with SLE and their correlation with the disease activity","volume":"133","author":"Zhao","year":"2020","journal-title":"Cytokine"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.12.8844","article-title":"Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis","volume":"177","author":"Wan","year":"2006","journal-title":"J Immunol (Baltimore Md.: 1950)"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-014-0497-x","article-title":"Synovial T cell hyporesponsiveness to myeloid dendritic cells is reversed by preventing PD-1\/PD-L1 interactions","volume":"16","author":"Moret","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1002\/art.27500","article-title":"The programmed death 1\/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis","volume":"62","author":"Raptopoulou","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.2337\/db07-1260","article-title":"Protective role of programmed death 1 ligand 1 (PD-L1)in nonobese diabetic mice: the paradox in transgenic models","volume":"57","author":"Wang","year":"2008","journal-title":"Diabetes"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.2337\/db12-1475","article-title":"PD-1, but not PD-L1, expressed by islet-reactive CD4+ T cells suppresses infiltration of the pancreas during type 1 diabetes","volume":"62","author":"Pauken","year":"2013","journal-title":"Diabetes"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0505497102","article-title":"Establishment of NOD-Pdcd1-\/- mice as an efficient animal model of type I diabetes","volume":"102","author":"Wang","year":"2005","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12603","article-title":"Low programmed cell death-1 (PD-1) expression in peripheral CD4(+) T cells in Japanese patients with autoimmune type 1 diabetes","volume":"180","author":"Fujisawa","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20022119","article-title":"Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis","volume":"198","author":"Salama","year":"2003","journal-title":"J Exp Med"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.20881","article-title":"Estrogen-mediated immunomodulation involves reduced activation of effector T cells, potentiation of Treg cells, and enhanced expression of the PD-1 costimulatory pathway","volume":"84","author":"Polanczyk","year":"2006","journal-title":"J Neurosci Res"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200324228","article-title":"Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses","volume":"33","author":"Liang","year":"2003","journal-title":"Eur J Immunol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901038","article-title":"Costimulatory pathways in multiple sclerosis: distinctive expression of PD-1 and PD-L1 in patients with different patterns of disease","volume":"183","author":"Trabattoni","year":"2009","journal-title":"J Immunol (Baltimore Md.: 1950)"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00608","article-title":"SLE: another autoimmune disorder influenced by microbes and diet","volume":"6","author":"Mu","year":"2015","journal-title":"Front Immunol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s00262-025-04078-0","article-title":"Impact of rheumatoid factors on the function of therapeutic monoclonals specific for PD-1\/PD-L1","volume":"74","author":"Hock","year":"2025","journal-title":"Cancer Immunol Immunother: CII"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13755","article-title":"PD-1: A critical player and target for immune normalization","volume":"172","author":"Liu","year":"2024","journal-title":"Immunology"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1080\/08916930500124072","article-title":"PD-1\/PD-L pathway and autoimmunity","volume":"38","author":"Okazaki","year":"2005","journal-title":"Autoimmunity"},{"key":"B94","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12929-024-01024-7","article-title":"T cell expressions of aberrant gene signatures and Co-inhibitory receptors (Co-IRs) as predictors of renal damage and lupus disease activity","volume":"31","author":"Wang","year":"2024","journal-title":"J Biomed Sci"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1387975","article-title":"Regulation of Treg cells by cytokine signaling and co-stimulatory molecules","volume":"15","author":"Zong","year":"2024","journal-title":"Front Immunol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abo1930","article-title":"Host-derived mannose glycans trigger a pathogenic \u03b3\u03b4 T cell\/IL-17a axis in autoimmunity","volume":"15","author":"Alves","year":"2023","journal-title":"Sci Trans Med"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1172\/jci160025","article-title":"mTOR regulates T cell exhaustion and PD-1-targeted immunotherapy response during chronic viral infection","volume":"133","author":"Ando","year":"2023","journal-title":"J Clin Invest"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M117.793885","article-title":"Hormonal vitamin D up-regulates tissue-specific PD-L1 and PD-L2 surface glycoprotein expression in humans but not mice","volume":"292","author":"Dimitrov","year":"2017","journal-title":"J Biol Chem"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200324270","article-title":"Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis","volume":"33","author":"Rodig","year":"2003","journal-title":"Eur J Immunol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13075-016-0942-0","article-title":"PD-L1-expressing neutrophils as a novel indicator to assess disease activity and severity of systemic lupus erythematosus","volume":"18","author":"Luo","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003503","article-title":"PD-1\/PD-L1 governed cross-talk of exhausted CD8(+) T and memory B cells in systemic lupus erythematosus","volume":"10","author":"Wang","year":"2024","journal-title":"RMD Open"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.102392","article-title":"An overview of autoantibodies in rheumatoid arthritis","volume":"110","author":"van Delft","year":"2020","journal-title":"J Autoimmun"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20161427","article-title":"PD-L1 up-regulation restrains Th17 cell differentiation in STAT3 loss- and STAT1 gain-of-function patients","volume":"214","author":"Zhang","year":"2017","journal-title":"J Exp Med"},{"key":"B104","doi-asserted-by":"publisher","first-page":"e13245","DOI":"10.1111\/sji.13245","article-title":"Galectin-3 interacts with PD-1 and counteracts the PD-1 pathway-driven regulation of T cell and osteoclast activity in Rheumatoid Arthritis","volume":"97","author":"Pedersen","year":"2023","journal-title":"Scand J Immunol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2017.8204","article-title":"Elevated expression of PD\u22121 on T cells correlates with disease activity in rheumatoid arthritis","volume":"17","author":"Luo","year":"2018","journal-title":"Mol Med Rep"},{"key":"B106","doi-asserted-by":"publisher","first-page":"R255","DOI":"10.1186\/ar4100","article-title":"A regulatory effect of IL-21 on T follicular helper-like cell and B cell in rheumatoid arthritis","volume":"14","author":"Liu","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.18502\/ijaai.v21i6.11524","article-title":"MicroRNAs targeting programmed cell death protein 1 (PD-1) promote natural killer cell exhaustion in rheumatoid arthritis","volume":"21","author":"Hemmatzadeh","year":"2022","journal-title":"Iranian J Allergy Asthma Immunol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1038\/s41467-024-46195-x","article-title":"Single-cell profiling identifies IL1B(hi) macrophages associated with inflammation in PD-1 inhibitor-induced inflammatory arthritis","volume":"15","author":"Zhou","year":"2024","journal-title":"Nat Commun"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2025.03.023","article-title":"Immuno-engineered macrophage membrane-coated nanodrug to restore immune balance for rheumatoid arthritis treatment","volume":"197","author":"Zhong","year":"2025","journal-title":"Acta Biomater"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1111005","article-title":"The effect of combining PD-1 agonist and low-dose Interleukin-2 on treating systemic lupus erythematosus","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1053\/j.gastro.2024.03.007","article-title":"Genetic deletion of galectin-3 inhibits pancreatic cancer progression and enhances the efficacy of immunotherapy","volume":"167","author":"Yang","year":"2024","journal-title":"Gastroenterology"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2024.152582","article-title":"Immune checkpoint inhibitors and rheumatoid arthritis: All roads lead to PD-1","author":"Cappelli","year":"2025","journal-title":"Semin Arthritis Rheum"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1285554","article-title":"Immune checkpoints in rheumatoid arthritis: progress and promise","volume":"14","author":"Small","year":"2023","journal-title":"Front Immunol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1172\/jci169309","article-title":"Anti-PD-1 chimeric antigen receptor T cells efficiently target SIV-infected CD4+ T cells in germinal centers","volume":"134","author":"Eichholz","year":"2024","journal-title":"J Clin Invest"},{"key":"B115","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.addr.2018.12.003","article-title":"Advances in immunotherapy of type I diabetes","volume":"139","author":"Ni","year":"2019","journal-title":"Adv Drug Deliv Rev"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1090842","article-title":"Mechanisms and therapeutic strategies of immune checkpoint molecules and regulators in type 1 diabetes","volume":"13","author":"Ding","year":"2022","journal-title":"Front Endocrinol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-024-06313-2","article-title":"Beta cell extracellular vesicle PD-L1 as a novel regulator of CD8(+) T cell activity and biomarker during the evolution of type 1 diabetes","volume":"68","author":"Rao","year":"2025","journal-title":"Diabetologia"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20051776","article-title":"Tissue expression of PD-L1 mediates peripheral T cell tolerance","volume":"203","author":"Keir","year":"2006","journal-title":"J Exp Med"},{"key":"B119","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cellimm.2016.09.009","article-title":"PD-1\/PD-L and autoimmunity: A growing relationship","volume":"310","author":"Zamani","year":"2016","journal-title":"Cell Immunol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"e1907692","DOI":"10.1002\/adma.201907692","article-title":"Engineered PD-L1-expressing platelets reverse new-onset type 1 diabetes","volume":"32","author":"Zhang","year":"2020","journal-title":"Adv Mater (Deerfield Beach Fla.)"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-021-02495-7","article-title":"Role of the PD-1\/PD-L1 signaling in multiple sclerosis and experimental autoimmune encephalomyelitis: recent insights and future directions","volume":"58","author":"Mi","year":"2021","journal-title":"Mol Neurobiol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"e2451212","DOI":"10.1002\/eji.202451212","article-title":"PD-1 regulation of pathogenic IL-17-secreting \u03b3\u03b4 T cells in experimental autoimmune encephalomyelitis","volume":"54","author":"Leane","year":"2024","journal-title":"Eur J Immunol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1110672","article-title":"Characterization of antigen-specific CD8+ memory T cell subsets in peripheral blood of patients with multiple sclerosis","volume":"14","author":"Liu","year":"2023","journal-title":"Front Immunol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1038\/ng1020","article-title":"A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans","volume":"32","author":"Prokunina","year":"2002","journal-title":"Nat Genet"},{"key":"B125","doi-asserted-by":"publisher","first-page":"R163","DOI":"10.1186\/ar2071","article-title":"Association of the programmed cell death 1 (PDCD1) gene polymorphism with ankylosing spondylitis in the Korean population","volume":"8","author":"Lee","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.111717","article-title":"Preclinical development and clinical studies of targeted JAK\/STAT combined Anti-PD-1\/PD-L1 therapy","volume":"130","author":"Chen","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B127","doi-asserted-by":"publisher","first-page":"24","DOI":"10.5114\/ceji.2025.149377","article-title":"PD-1\/PD-L1 inhibitor treatment associated with cardiotoxicity regulated by macrophage polarization and SOCS3\/JAK\/STAT3 signaling pathway","volume":"50","author":"Fu","year":"2025","journal-title":"Central-European J Immunol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1002\/clc.24149","article-title":"Plasma exchange plus glucocorticoids in the treatment of immune checkpoint inhibitor-induced myocarditis: A case series and review","volume":"46","author":"Ke","year":"2023","journal-title":"Clin Cardiol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.115162","article-title":"Toward immune tolerance in rheumatoid arthritis: Emerging immunotherapies and targets for long-term remission","volume":"162","author":"Afshari","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"B130","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1136\/gutjnl-2024-332919","article-title":"Cellular immunotherapies and immune cell depleting therapies in inflammatory bowel diseases: the next magic bullet","volume":"74","author":"Neurath","year":"2024","journal-title":"Gut"},{"key":"B131","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41392-023-01350-6","article-title":"Low-dose IL-2 mitigates glucocorticoid-induced Treg impairment and promotes improvement of SLE","volume":"8","author":"Zhou","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B132","doi-asserted-by":"publisher","first-page":"e1165","DOI":"10.1002\/iid3.1165","article-title":"Efficacy, safety and the lymphocyte subsets changes of low-dose IL-2 in patients with systemic lupus erythematosus: A systematic review and meta-analysis","volume":"12","author":"Su","year":"2024","journal-title":"Immun Inflammation Dis"},{"key":"B133","doi-asserted-by":"publisher","first-page":"6074","DOI":"10.1038\/ncomms7074","article-title":"Regulation of T-cell activation and migration by the kinase TBK1 during neuroinflammation","volume":"6","author":"Yu","year":"2015","journal-title":"Nat Commun"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-025-01373-0","article-title":"Generation of tolerogenic antigen-presenting cells in vivo via the delivery of mRNA encoding PDL1 within lipid nanoparticles","volume":"9","author":"Liu","year":"2025","journal-title":"Nat Biomed Eng"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.2147\/ijn.S522245","article-title":"Stem cell-derived exosomes with high expression of PD-L1 as nanotherapeutics in rheumatoid arthritis model mice","volume":"20","author":"Wang","year":"2025","journal-title":"Int J Nanomed"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-023-06076-2","article-title":"Genetic engineering of regulatory T cells for treatment of autoimmune disorders including type 1 diabetes","volume":"67","author":"Tuomela","year":"2024","journal-title":"Diabetologia"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00612-0","article-title":"IL-2R\u03b1-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25(+)CD8(+) T cells","volume":"4","author":"Wu","year":"2023","journal-title":"Nat Cancer"},{"key":"B138","doi-asserted-by":"publisher","first-page":"e07167","DOI":"10.1002\/advs.202507167","article-title":"PLAUR(+) neutrophils drive anti-PD-1 therapy resistance in patients with hepatocellular carcinoma by shaping an immunosuppressive microenvironment","volume":"12","author":"Liu","year":"2025","journal-title":"Adv Sci (Weinheim Baden-Wurttemberg Germany)"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-24-3748","article-title":"Prostate cancer cells secrete PD-1 in exosomes to enhance myeloid-derived suppressor cell activity and promote tumor immune evasion","volume":"85","author":"Zhang","year":"2025","journal-title":"Cancer Res"},{"key":"B140","doi-asserted-by":"publisher","first-page":"e01341","DOI":"10.1002\/advs.202501341","article-title":"Targeting IGF1R overcomes armored and cold tumor microenvironment and boosts immune checkpoint blockade in triple-negative breast cancer","volume":"12","author":"Wan","year":"2025","journal-title":"Adv Sci (Weinheim Baden-Wurttemberg Germany)"},{"key":"B141","doi-asserted-by":"publisher","first-page":"eadg6752","DOI":"10.1126\/scitranslmed.adg6752","article-title":"Identification of a small-molecule Tim-3 inhibitor to potentiate T cell-mediated antitumor immunotherapy in preclinical mouse models","volume":"15","author":"Ma","year":"2023","journal-title":"Sci Trans Med"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0756-0","article-title":"FBXO38 mediates PD-1 ubiquitination and regulates anti-tumour immunity of T cells","volume":"564","author":"Meng","year":"2018","journal-title":"Nature"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1038\/s44319-024-00220-8","article-title":"FBXO38 is dispensable for PD-1 regulation","volume":"25","author":"Dibus","year":"2024","journal-title":"EMBO Rep"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2024.100973","article-title":"FBXO38 deficiency promotes lysosome-dependent STING degradation and inhibits cGAS-STING pathway activation","volume":"49","author":"Wu","year":"2024","journal-title":"Neoplasia (New York N.Y.)"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1080\/08820130902912332","article-title":"Soluble PD-1 is associated with aberrant regulation of T cells activation in aplastic anemia","volume":"38","author":"Wu","year":"2009","journal-title":"Immunol Invest"},{"key":"B146","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3892\/br.2025.1948","article-title":"High serum levels of soluble PD\u22121 and PD\u2212L1 are associated with advanced clinical stages in patients with cervical cancer","volume":"22","author":"P\u00e9rez-Picazo","year":"2025","journal-title":"Biomed Rep"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209856","article-title":"A phase 2 trial of peresolimab for adults with rheumatoid arthritis","volume":"388","author":"Tuttle","year":"2023","journal-title":"New Engl J Med"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.152468","article-title":"Cell-targeted PD-1 agonists that mimic PD-L1 are potent T cell inhibitors","volume":"6","author":"Curnock","year":"2021","journal-title":"JCI Insight"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.06.008","article-title":"Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142","volume":"33","author":"Andr\u00e9","year":"2022","journal-title":"Ann Oncol"},{"key":"B150","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41392-022-01022-x","article-title":"Nivolumab plus ipilimumab: a potential regimen to rewrite treatment guidelines for ESCC","volume":"7","author":"Luo","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable Malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet (London England)"},{"key":"B152","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.3747\/co.27.5135","article-title":"Use of immuno-oncology in melanoma","volume":"27","author":"Smylie","year":"2020","journal-title":"Curr Oncol (Toronto Ont.)"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-024-01301-3","article-title":"Harnessing IL-2 for immunotherapy against cancer and chronic infection: a historical perspective and emerging trends","volume":"56","author":"Im","year":"2024","journal-title":"Exp Mol Med"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13842","article-title":"Combination immunotherapy with interleukin-2 surface-modified tumor cell vaccine and programmed death receptor-1 blockade against renal cell carcinoma","volume":"110","author":"Zhang","year":"2019","journal-title":"Cancer Sci"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnesp.2024.03.036","article-title":"Synergistic effects of \u03a9-3 polyunsaturated fatty acid supplementation and programmed cell death protein 1 blockade on tumor growth and immune modulation in a xenograft model of esophageal cancer","volume":"61","author":"Xiao","year":"2024","journal-title":"Clin Nutr ESPEN"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-013-1391-0","article-title":"Modulation of p38 MAPK signaling enhances dendritic cell activation of human CD4+ Th17 responses to ovarian tumor antigen","volume":"62","author":"Cannon","year":"2013","journal-title":"Cancer Immunol Immunother: CII"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1007\/s12010-024-04904-8","article-title":"Modulation of T cell differentiation in mice with COPD combined with lung cancer through key targets of PD-1 by tao hong si wu tang","volume":"196","author":"Wang","year":"2024","journal-title":"Appl Biochem Biotechnol"},{"key":"B158","doi-asserted-by":"publisher","first-page":"4223","DOI":"10.1038\/s41467-023-39938-9","article-title":"mRNA lipid nanoparticle-mediated pyroptosis sensitizes immunologically cold tumors to checkpoint immunotherapy","volume":"14","author":"Li","year":"2023","journal-title":"Nat Commun"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01539","article-title":"Induction of Robust B Cell Responses after Influenza mRNA Vaccination Is Accompanied by Circulating Hemagglutinin-Specific ICOS+ PD-1+ CXCR3+ T Follicular Helper Cells","volume":"8","author":"Lindgren","year":"2017","journal-title":"Front Immunol"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1415102","article-title":"CD39 delineates chimeric antigen receptor regulatory T cell subsets with distinct cytotoxic & regulatory functions against human islets","volume":"15","author":"Wu","year":"2024","journal-title":"Front Immunol"},{"key":"B161","doi-asserted-by":"publisher","first-page":"0718_6289","DOI":"10.4049\/jimmunol.212.supp.0718.6289","article-title":"GenSci120, a humanized PD-1 agonistic monoclonal antibody, enhances the binding of both PD-L1 and PD-L2 to PD-1, and mitigates the symptoms of GVHD in a mouse model","volume":"212","author":"Jiang","year":"2024","journal-title":"J Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1707084\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T06:47:04Z","timestamp":1771915624000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1707084\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":161,"alternative-id":["10.3389\/fimmu.2026.1707084"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1707084","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"article-number":"1707084"}}